[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Kummar S, Ciesielski TE, Fogarasi MC: Management of small bowel adenocarcinoma. Oncology (Williston Park); 2002 Oct;16(10):1364-9; discussion 1370, 1372-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of small bowel adenocarcinoma.
  • Small bowel adenocarcinoma is a relatively rare malignancy.
  • Only limited information is available on the incidence, prognosis, and role of chemotherapy in the treatment of this disease.
  • We present a review of currently available clinical data to assist the practicing oncologist in the treatment of these patients.
  • Approximately 5,300 new cases and 1,100 deaths from small bowel adenocarcinoma are reported annually in the United States.
  • Factors associated with poor prognosis are age > 75 years, lack of surgical resection, advanced stage, and tumor arising in the duodenum.
  • Few data exist on the use of (neo)adjuvant or palliative chemo(radio)therapy in this setting.
  • Fluorouracil (5-FU)based chemotherapy, as a single agent or in combination with others, has been used in most case series.
  • Duodenal adenocarcinoma accounts for more than 50% of all cases of small bowel adenocarcinoma.
  • Resectability is the key prognostic factor, along with age, performance status, tumor location, and presence of distant metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12435206.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


2. Kim JW, Park JH, Cho HJ, Kwon JH, Koh Y, Kim SJ, Kim SH, Lee SH, Im SA, Kim YT, Kim WH: A case of desmoplastic small round cell tumor diagnosed in a young female patient. Cancer Res Treat; 2009 Dec;41(4):233-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of desmoplastic small round cell tumor diagnosed in a young female patient.
  • Desmoplastic small round cell tumor is a very rare malignancy.
  • We performed an endoscopic biopsy of the duodenal mass and diagnosed her disease as desmoplastic small round cell tumor using immunohistochemical staining, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction.
  • Because the mass invaded the pancreas and superior mesenteric vein as well as duodenum and the disease was disseminated to liver and peritoneum, she received palliative chemotherapy using vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide.
  • The maximal response to chemotherapy was stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1992 Apr;16(4):411-6 [1314522.001]
  • [Cites] Am J Clin Pathol. 1991 Oct;96(4):536-43 [1716417.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1363-6 [8608516.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):293-8 [8689345.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1159-61 [14520438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):170-6 [12182988.001]
  • [Cites] Histopathology. 1991 Dec;19(6):560-2 [1786939.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):413-21 [2469334.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1526-31 [8622067.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2181-8 [11956280.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • (PMID = 20057970.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2802845
  • [Keywords] NOTNLM ; Chemotherapy / Desmoplastic small round cell tumor / Fluorescence in situ hybridization / Reverse transcriptase polymerase chain reaction
  •  go-up   go-down


3. Shelat VG, Diddapur RK: Duodenal carcinoid: a rare cause of melaena in a cirrhotic patient. Singapore Med J; 2008 Aug;49(8):e198-201
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal carcinoid: a rare cause of melaena in a cirrhotic patient.
  • Small intestinal neuroendocrine tumours are relatively rare.
  • These are indolent tumours and hence role of chemotherapy is limited.
  • Radionuclide and biological therapies are emerging.
  • Standard Whipple's procedure was done and he is doing well at follow-up.
  • [MeSH-major] Carcinoid Tumor / complications. Duodenal Neoplasms / complications. Liver Cirrhosis / diagnosis. Liver Cirrhosis / therapy. Melena / diagnosis. Melena / etiology. Neuroendocrine Tumors / complications
  • [MeSH-minor] Adult. Duodenum / pathology. Endoscopy / methods. Humans. Male. Neoplasm Metastasis. Prognosis. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756332.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


Advertisement
4. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • Chest X-ray revealed multiple emphysematous bullae in both lungs and a tumor shadow in the right upper lobe.
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Although chemotherapy and radiotherapy resulted in decrease in tumor size, the tumor subsequently increased in size and the patient died 14 months after the first admission.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • It has also been suggested that the genetic abnormality responsible for von Recklinghausen's disease increases the risk for various types of malignancy.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827584.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


5. Gong LS, Zhang YD, Liu S: Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model. Hepatobiliary Pancreat Dis Int; 2004 Aug;3(3):365-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to verify the effect of magnetic field application on target distribution of nanoparticles in transplanted rat liver cancer model and to find out a new method for the treatment of malignant liver tumor.
  • A cannula was inserted into the gastro-duodenal artery.
  • In the experimental group (12 rats), the tumor tissue was exposed to the magnetic field for 30 minutes.
  • Tissues of tumor, nontargeted sites of the liver, heart, kidney, lung, spleen, stomach and small intestine were analyzed for gamma-counts and examined histologically.
  • RESULTS: In the experimental group, the radioactivity of tumor tissue was 8.7 times that of liver tissue.
  • In the control group, the radioactivity of tumor tissue was 2.8 times that of normal liver tissue.
  • No significant difference in the kidney, heart, spleen, small intestine and stomach was observed between the experimental group and control group.
  • CONCLUSIONS: In the presence of magnetic field, magnetic albumin nanoparticles may accumulate in tumor tissues, of which the radioactivity can increase to 8.7 times that of normal liver.
  • Even if the magnetic field is not applied, magnetic albumin nanoparticles in tumor tissues still increase to 2.8 times that of normal liver tissues.
  • These findings indicate that normal organs in the presence of magnetic field are less exposed to chemotherapeutic drugs.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Carcinoma 256, Walker / drug therapy. Carcinoma, Hepatocellular / drug therapy. Doxorubicin / pharmacokinetics. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313670.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Albumins; 0 / Antimetabolites, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


6. Zenda T, Masunaga T, Fuwa B, Okada T, Ontachi Y, Kondo Y, Nakao S, Minato H: Small follicular lymphoma arising near the ampulla of vater: a distinct subtype of duodenal lymphoma? Int J Gastrointest Cancer; 2005;36(2):113-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small follicular lymphoma arising near the ampulla of vater: a distinct subtype of duodenal lymphoma?
  • Endoscopy revealed a flat elevated lesion about 15 mm in diameter adjacent to the duodenal papilla, the surface of which was uneven and covered with whitish granules.
  • Systemic staging examinations suggested the lymphoma was restricted to the mucosa and superficial portion of the submucosa in the duodenal wall.
  • The patient was treated with a combination of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and monoclonal anti-CD20 antibody (rituximab), in addition to radiotherapy.
  • After six courses of this combination chemotherapy, complete regression of the lymphoma was observed.
  • Although reports of small duodenal lymphoma (<20 mm or localized to the mucosa or submucosa) are extremely rare, the features of this case are characteristic of small duodenal lymphoma in terms of evolution around the ampulla of Vater, low-grade follicular type, occurrence in a women, occurrence in the fourth decade of life, and favorable outcome, and this type of tumor may need to be distinguished by pathogenesis and clinical behavior from various other gastrointestinal lymphomas.
  • [MeSH-major] Ampulla of Vater / pathology. Duodenal Neoplasms / diagnosis. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Endoscopy, Gastrointestinal. Female. Humans. Immunochemistry. Japan. Middle Aged. Radiography. Treatment Outcome


7. Croci T, Landi M, Galzin AM, Marini P: Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol; 2003 Sep;140(1):115-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.
  • (1) We investigated the effect of the cannabinoid CB1 receptor antagonist, SR 141716, on indomethacin-induced small intestine inflammation and Escherichia coli lipopolysaccharide (LPS)-induced plasma TNF-alpha (TNF) release in comparison to the cannabinoid CB2 receptor antagonist, SR 144528, in rodents. (2) In rats, indomethacin induced significant ulcer formation in the small intestine; this was accompanied by an increase in tissue TNF levels and myeloperoxidase (MPO) activity.
  • SR 144528 prevented intestinal ulcers only. (3) The effect of SR 141716 against indomethacin-induced ulcers and increase of plasma TNF levels after LPS was also studied in wild-type and CB1 receptor knockout mice.
  • Indomethacin induced intestinal ulcers in mice, but not tissue TNF production and MPO activity.
  • SR 141716 reduced the ulcers to a similar extent in wild-type and CB1 receptor knockout mice.
  • In rats and wild-type mice, but not in CB1 receptor knockout mice, SR 141716 inhibited the LPS-induced increase in plasma TNF levels. (4) These findings provide evidence that the indomethacin model of intestinal lesions differs in rat and mouse and support the existence of several mechanisms for the antiulcer activity of SR141716, the most important involving the inhibition of TNF production.
  • The potent anti-inflammatory activity of SR141716 in rodents indicated its potential therapeutic interest in chronic immune-inflammatory diseases.
  • [MeSH-major] Duodenal Ulcer / prevention & control. Intestine, Small / metabolism. Piperidines / pharmacology. Pyrazoles / pharmacology. Receptor, Cannabinoid, CB1 / antagonists & inhibitors. Receptor, Cannabinoid, CB1 / physiology. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] Animals. Anti-Inflammatory Agents / pharmacology. Anti-Inflammatory Agents / therapeutic use. Dose-Response Relationship, Drug. Duodenitis / chemically induced. Duodenitis / drug therapy. Duodenitis / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Rats

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1982 Sep;60(3):618-22 [6286012.001]
  • [Cites] Life Sci. 1999;65(6-7):637-44 [10462064.001]
  • [Cites] Biometrics. 1986 Sep;42(3):575-82 [3567290.001]
  • [Cites] Lab Invest. 1987 Jun;56(6):583-90 [3599906.001]
  • [Cites] Mol Pharmacol. 1988 Nov;34(5):605-13 [2848184.001]
  • [Cites] Mol Pharmacol. 1992 Nov;42(5):736-42 [1279376.001]
  • [Cites] Eur J Biochem. 1993 May 15;214(1):173-80 [8508790.001]
  • [Cites] Nature. 1993 Sep 2;365(6441):61-5 [7689702.001]
  • [Cites] Scand J Gastroenterol. 1993 Sep;28(9):795-802 [8235436.001]
  • [Cites] Agents Actions. 1993;39 Spec No:C145-7 [7505999.001]
  • [Cites] FEBS Lett. 1994 Aug 22;350(2-3):240-4 [8070571.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:607-34 [7598509.001]
  • [Cites] J Physiol Pharmacol. 1999 Mar;50(1):25-38 [10210152.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):54-61 [7556170.001]
  • [Cites] Eur J Pharmacol. 1996 Apr 11;300(3):227-36 [8739213.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22330-9 [9268384.001]
  • [Cites] Pharmacol Ther. 1997;74(2):129-80 [9336020.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Feb;284(2):644-50 [9454810.001]
  • [Cites] Pain. 1998 Mar;75(1):111-9 [9539680.001]
  • [Cites] FASEB J. 1998 Aug;12(11):1035-44 [9707176.001]
  • [Cites] Life Sci. 1998;63(8):PL125-9 [9718090.001]
  • [Cites] Br J Pharmacol. 1998 Aug;124(7):1385-94 [9723949.001]
  • [Cites] Br J Pharmacol. 1998 Dec;125(7):1393-5 [9884065.001]
  • [Cites] Science. 1999 Jan 15;283(5400):401-4 [9888857.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):65-70 [9933153.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):473-80 [10051530.001]
  • [Cites] Eur J Pharmacol. 2000 Jan 17;387(3):343-7 [10650181.001]
  • [Cites] Horm Metab Res. 1999 Dec;31(12):626-31 [10668912.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Apr;293(1):136-50 [10734163.001]
  • [Cites] Eur J Pharmacol. 2000 Aug 4;401(2):121-30 [10924916.001]
  • [Cites] J Neuroimmunol. 2000 Sep 22;109(2):155-63 [10996217.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Oct;225(1):1-8 [10998193.001]
  • [Cites] Cell Tissue Res. 2000 Oct;302(1):73-80 [11079717.001]
  • [Cites] Gut. 2001 Jun;48(6):859-67 [11358910.001]
  • [Cites] Life Sci. 2001 May 25;69(1):101-11 [11411800.001]
  • [Cites] Br J Pharmacol. 2001 Oct;134(3):563-70 [11588110.001]
  • [Cites] Eur J Pharmacol. 2001 Aug 3;425(1):73-83 [11672577.001]
  • [Cites] Eur J Pharmacol. 2001 Nov 30;432(1):107-19 [11734194.001]
  • [Cites] Br J Pharmacol. 2002 Jan;135(1):181-7 [11786493.001]
  • [Cites] Science. 2002 Apr 26;296(5568):678-82 [11976437.001]
  • [Cites] Pharmacol Rev. 2002 Jun;54(2):161-202 [12037135.001]
  • [Cites] Dig Liver Dis. 2002 Apr;34(4):262-9 [12038810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8384-8 [12060781.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):227-34 [12105851.001]
  • [Cites] Eur J Pharmacol. 2002 Aug 16;450(1):77-83 [12176112.001]
  • [Cites] Inflamm Res. 2002 Dec;51(12):603-10 [12558194.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5780-5 [10318961.001]
  • [Cites] Science. 1986 Oct 24;234(4775):470-4 [3764421.001]
  • (PMID = 12967941.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 0 / Tumor Necrosis Factor-alpha; 158681-13-1 / rimonabant
  • [Other-IDs] NLM/ PMC1574010
  •  go-up   go-down


8. Ono M, Shirao K, Takashima A, Morizane C, Okita N, Takahari D, Hirashima Y, Eguchi-Nakajima T, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer; 2008;11(4):201-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
  • BACKGROUND: Small-bowel adenocarcinoma (SBA) is a rare tumor that has a poor response to chemotherapy and a poor prognosis.
  • Treatment strategies for SBA have not been clearly established.
  • METHODS: All patients with SBA treated using a combination of cisplatin and irinotecan (IP) as first-line chemotherapy at the National Cancer Center Hospital in Japan between January 1999 and February 2007 were studied retrospectively.
  • RESULTS: Eight patients received IP as first-line chemotherapy.
  • The median time to treatment failure was 4.5 months (95% confidence interval, 0.9-5.8 months), and overall survival was 17.3 months (range, 1.9-21.3 months).
  • CONCLUSION: IP combination chemotherapy may be an acceptable option for patients with SBA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Intestinal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / mortality. Female. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / mortality. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / mortality. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Clin Colorectal Cancer. 2004 Nov;4(4):241-8; discussion 249-51 [15555205.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):921-7 [9060529.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):116-28 [3285475.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):625-39 [12134621.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • (PMID = 19132481.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Isomoto H, Ohnita K, Mizuta Y, Maeda T, Onizuka Y, Miyazaki M, Omagari K, Takeshima F, Murase K, Haraguchi M, Murata I, Kohno S: Clinical and endoscopic features of adult T-cell leukemia/lymphoma with duodenal involvement. J Clin Gastroenterol; 2001 Sep;33(3):241-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and endoscopic features of adult T-cell leukemia/lymphoma with duodenal involvement.
  • We describe three cases of adult T-cell leukemia/lymphoma (ATLL) with duodenal involvement and provide a review of the literature.
  • The second case, a 70-year-old man with lymphoma subtype of ATLL, had a polypoid tumor in the descending portion of the duodenum and multiple protruded lesions in the small and large intestines.
  • All patients received combination chemotherapy, which was successful in the first and third cases, accompanied by the disappearance of gastroduodenal lesions.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endoscopy, Gastrointestinal. Female. Humans. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / drug therapy. Male. Middle Aged. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11500618.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


10. Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taïeb J, Bonnetain F, Aparicio T: Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol; 2010 Sep;21(9):1786-93
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
  • BACKGROUND: Small-bowel adenocarcinoma (SBA) is a rare tumor of poor prognosis.
  • Data on the efficacy of chemotherapy for advanced SBA are scarce.
  • PATIENTS AND METHODS: All patients with advanced SBA who received frontline chemotherapy from 1996 to 2008 were eligible for this retrospective multicenter study.
  • In the entire population, the median progression-free survival (PFS) and overall survival (OS) times were 6.6 and 15.1 months, respectively.
  • Median PFS times among patients treated with LV5FU2 (n = 10), FOLFOX (n = 48), FOLFIRI (n = 19) and LV5FU2-cisplatin (n = 16) were 7.7, 6.9, 6.0 and 4.8 months, respectively, while median OS times were 13.5, 17.8, 10.6 and 9.3 months, respectively.
  • In the subgroup of patients treated with platinum-based chemotherapy, multivariate analysis showed that LV5FU2-cisplatin was associated with poorer PFS (P < 0.0001) and OS (P = 0.02) compared with FOLFOX.
  • CONCLUSIONS: This is the largest study of chemotherapy in advanced SBA.
  • FOLFOX seems to be the most effective platinum-based chemotherapy regimen.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223786.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Bettini AC, Beretta GD, Sironi P, Mosconi S, Labianca R: Chemotherapy in small bowel adenocarcinoma associated with celiac disease: a report of three cases. Tumori; 2003 Mar-Apr;89(2):193-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in small bowel adenocarcinoma associated with celiac disease: a report of three cases.
  • Tumors of the small intestine are rare and usually occur in association with genetic disease and chronic intestinal inflammation.
  • We report three cases of small bowel adenocarcinoma in patients affected by celiac disease who received a safe chemotherapy regimen (FOLFOX IV or LV5FU2) after tumor resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Celiac Disease / complications. Duodenal Neoplasms / drug therapy. Jejunal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12841670.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Lendel I, Manni A, Ruggiero FM: Novel association of duodenal gastrinoma and atrophic gastritis: case report and literature review. Endocr Pract; 2007 Nov-Dec;13(7):770-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel association of duodenal gastrinoma and atrophic gastritis: case report and literature review.
  • OBJECTIVE: To describe a patient with a duodenal gastrinoma in a setting of atrophic gastritis and hypergastrinemia.
  • METHODS: We present historical features and results of laboratory and genetic evaluation in a woman with duodenal gastrinoma and hypergastrinemia due to atrophic gastritis.
  • RESULTS: In a 46-year-old woman with a history of stable pituitary microprolactinoma, multiple gastrointestinal symptoms developed and prompted the performance of an esophagogastroduodenoscopy in conjunction with small bowel biopsies.
  • A 2-mm duodenal gastrin-producing neuroendocrine tumor was discovered.
  • The tumor stained negative for serotonin and somatostatin and involved the mucosa and submucosa.
  • Immunohistochemical staining of the gastrinoma tissue with a monoclonal antibody to the cholecystokinin-B (gastrin) receptor was negative.
  • After pantoprazole therapy was discontinued, the serum gastrin level remained elevated at 403 pg/mL.
  • There was no family history of multiple endocrine neoplasia type 1, and genetic testing for the MEN1 mutation was negative.
  • Gastrin is a well-recognized growth factor for many tissues.
  • We postulate that hypergastrinemia in this patient might have had a trophic effect on the duodenal G cells and led to gastrinoma development.
  • No gastrin receptors were detected on the gastrinoma cells; however, that result might have been attributable to technical (fixation or antibody) or tumor (dedifferentiation) problems.
  • [MeSH-major] Duodenal Neoplasms / complications. Gastrinoma / complications. Gastritis, Atrophic / complications
  • [MeSH-minor] Carcinoid Tumor / complications. Carcinoid Tumor / diagnosis. Carcinoid Tumor / secretion. Female. Gastrins / blood. Gastrins / secretion. Humans. Immunohistochemistry. Middle Aged. Pituitary Neoplasms / complications. Pituitary Neoplasms / drug therapy. Prolactinoma / complications. Prolactinoma / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for duodenal gastrinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194935.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins
  • [Number-of-references] 34
  •  go-up   go-down


13. Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T: Clinical features of and chemotherapy for cancer of the small intestine. Anticancer Res; 2010 Aug;30(8):3193-7
Genetic Alliance. consumer health - Small intestine cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of and chemotherapy for cancer of the small intestine.
  • BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated.
  • Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required.
  • This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy.
  • PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study.
  • Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded.
  • The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence.
  • Six patients underwent a partial resection of the small intestine, and a right hemicolectomy, and a bypass were performed in one case each.
  • The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm.
  • Six patients underwent postoperative chemotherapy.
  • One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of.
  • The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD).
  • CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection.
  • Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs.
  • Nevertheless, there is no established regimen for such chemotherapy.
  • Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success.
  • Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report.
  • The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871040.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


14. Lepicard A, Lamarque D, Lévy M, Copie-Bergman C, Chaumette MT, Haioun C, Anglade MC, Delchier JC: Duodenal mucosa-associated lymphoid tissue lymphoma: treatment with oral cyclophosphamide. Am J Gastroenterol; 2000 Feb;95(2):536-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal mucosa-associated lymphoid tissue lymphoma: treatment with oral cyclophosphamide.
  • Small cell mucosa-associated lymphoid tissue (MALT) lymphomas rarely affect the duodenum, and optimal treatment has not been defined.
  • The aim of this case series was to determine the clinical features and outcome of duodenal MALT lymphoma in four patients (three men, one woman; median age 52 yr) treated with cyclophosphamide p.o.
  • It was localized in the duodenum in three cases and involved the entire small bowel in one case.
  • Tumor infiltration was limited to the duodenal wall in one case and was associated with locoregional lymphadenopathy in three cases.
  • Gastroscopy with biopsies, radiography of the small intestine and abdominal CT (CT) were performed every 6 months.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / therapeutic use. Duodenal Neoplasms / drug therapy. Immunosuppressive Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Biopsy. Female. Follow-Up Studies. Gastroscopy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10685764.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


15. Yaguchi T, Imaeda H, Kizaki M, Hosoe N, Suzuki H, Ogata H, Iwao Y, Kameyama K, Ikeda Y, Hibi T: Partial regression of duodenal lesions of intestinal follicular lymphoma after antibiotic treatment. Dig Endosc; 2010 Oct;22(4):316-8
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial regression of duodenal lesions of intestinal follicular lymphoma after antibiotic treatment.
  • A 51-year-old man was referred to our hospital because of duodenal lesions of lymphoma.
  • A small bowel series showed multiple granular lesions extending from the second portion of the duodenum to the proximal jejunum and the proximal ileum.
  • On the basis of these findings, the tumor was diagnosed as stage I follicular lymphoma (FL).
  • Although the patient was negative for Helicobacter pylori, he underwent antibiotic treatment.
  • The lesions improved 3 months after antibiotic treatment, but biopsy specimens showed residual lymphoma cells.
  • The patient therefore received combination chemotherapy with rituximab.
  • The partial regression of duodenal lesions of intestinal FL may be due to the effect of antibiotic treatment.
  • [MeSH-major] 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use. Amoxicillin / therapeutic use. Anti-Infective Agents / therapeutic use. Clarithromycin / therapeutic use. Duodenal Neoplasms / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Drug Therapy, Combination. Endoscopy, Gastrointestinal. Humans. Lansoprazole. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Digestive Endoscopy © 2010 Japan Gastroenterological Endoscopy Society.
  • (PMID = 21175486.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Infective Agents; 0K5C5T2QPG / Lansoprazole; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin
  •  go-up   go-down


16. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Five years after the patient presented with melena and acute anemia; during endoscopic examination, a large bleeding duodenal polyp was found, so a surgical resection of the gastric antrum, duodenum, head of the pancreas, main bile ducts and gallbladder was performed.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • The ultrastructural analysis revealed small calcified electron-dense depots both in the perinuclear cytoplasm and in the extracellular collagen matrix compatible with an "early osteoid formation".
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia
  • [MeSH-minor] Adult. Duodenal Diseases / etiology. Duodenal Diseases / pathology. Humans. Intestinal Polyps / etiology. Intestinal Polyps / pathology. Male

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Huang CC, Yang CY, Lai IR, Chen CN, Lee PH, Lin MT: Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg; 2009 Apr;33(4):828-34
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era.
  • BACKGROUND: The small intestine, after the stomach, is the second most common primary site for gastrointestinal stromal tumors (GISTs).
  • This study aimed to identify clinicopathologic prognostic factors of tumor recurrence and survival and to analyze the influence of imatinib and sunitinib for small-intestine GISTs.
  • METHODS: We reviewed the surgical experience of patients with small-intestine GISTs at National Taiwan University Hospital from January 1995 to March 2007.
  • We analyzed the perioperative clinicopathologic data and treatment course.
  • The tumor was local in 43 patients, advanced in 21 patients, and 6 had metastasis.
  • The median size of the tumor was 6.5 cm.
  • According to multivariate analysis for disease recurrence, only invasion status, tumor size, and mitotic rate are significant (P=0.007, 0.035, 0.007 respectively).
  • CONCLUSIONS: The invasion status, size, and mitotic rate of tumor involve higher risk of recurrence and poor survival in small-intestine GISTs.
  • The patients with recurrent small-intestine GISTs may have a lower mortality rate after using imatinib and sunitinib.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Disease-Free Survival. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / pathology. Female. Gastrointestinal Agents / therapeutic use. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / pathology. Infliximab. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):50-9 [11206225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):477-89 [16625094.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Dig Surg. 2008;25(3):208-12 [18577866.001]
  • [Cites] Am Surg. 2006 Aug;72(8):719-22; discussion 722-3 [16913316.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Am J Clin Pathol. 1997 Dec;108(6):641-51 [9384445.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] BMC Gastroenterol. 2006 Oct 24;6:29 [17062131.001]
  • [Cites] J Formos Med Assoc. 2005 Dec;104(12):905-12 [16607447.001]
  • (PMID = 19198935.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


18. Oscarson M, Burk O, Winter S, Schwab M, Wolbold R, Dippon J, Eichelbaum M, Meyer UA: Effects of rifampicin on global gene expression in human small intestine. Pharmacogenet Genomics; 2007 Nov;17(11):907-18
Hazardous Substances Data Bank. RIFAMPIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of rifampicin on global gene expression in human small intestine.
  • OBJECTIVES: The small intestinal wall serves as an important barrier for the entry of foreign substances into the organism.
  • Of particular importance are enzymes and transporters that can inactivate or prevent the uptake of many xenobiotics including drugs.
  • The effect of the inducer drug rifampicin on intestinal cells was therefore evaluated both in vivo and in vitro.
  • METHODS: Seven healthy volunteers were treated with rifampicin for 9 days and the global gene expression profile was analysed in RNA from duodenal biopsies taken before and after drug treatment.
  • RESULTS: We identified 32 genes that were upregulated and two genes that were downregulated by rifampicin treatment in vivo.
  • The list of rifampicin regulated transcripts expectedly included drug metabolizing enzymes and drug transporters, but also genes involved in lipid and amino acid metabolism as well as genes not previously recognized to be part of the adaptation of intestinal cells to xenobiotic exposure.
  • CONCLUSION: The similarities and differences of changes in gene expression after rifampicin treatment between duodenal biopsies and cell culture provide a new assessment of the extent and diversity of systems affected by drug exposure.
  • [MeSH-major] Antibiotics, Antitubercular / pharmacology. Duodenum / drug effects. Gene Expression Regulation / drug effects. Rifampin / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers / metabolism. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Transcription, Genetic / drug effects. Transcription, Genetic / genetics. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism. Tumor Cells, Cultured / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075461.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antitubercular; 0 / Biomarkers; 0 / RNA, Messenger; VJT6J7R4TR / Rifampin
  •  go-up   go-down


19. Manfredi S, Thiebot T, Henno S, Falize L, Bretagne JF, Meunier B: Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen. J Gastrointest Surg; 2009 Dec;13(12):2309-13
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.
  • INTRODUCTION: The incidence of adenocarcinoma of the small bowel is very low in comparison with that of colorectal cancer.
  • Radical surgery is the only curative treatment, and results with chemotherapy and radiotherapy are disappointing.
  • No standard chemotherapy is defined for non-surgical adenocarcinoma of the small bowel.
  • In France, it is usually treated with the same chemotherapy regimens as used for colorectal cancer.
  • CASE REPORT: We report here the case of a young patient with an initially non-surgical adenocarcinoma of the duodenum treated in a palliative setting with the FOLFOX 4 chemotherapy regimen.
  • After 4 months of treatment, CT scan showed no residual tumor and the patient was well.
  • A multidisciplinary committee decided that a second surgical investigation was necessary, and a duodenal resection was performed, with no residual tumor in the final specimen.
  • CONCLUSION: The FOLFOX 4 regimen seems to be efficacious for some small-bowel adenocarcinomas and can be expected to lead to downstaging.
  • If the outcome of a few months of chemotherapy is favorable, it is appropriate for a multidisciplinary expert committee to consider further surgery.
  • This case underscores the value of multidisciplinary expert committees in scrutinizing therapeutic decisions in rare and difficult cases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Organoplatinum Compounds / therapeutic use. Palliative Care. Radiography

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2001 Jul;71(7):428-37 [11450920.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):699-701 [8172140.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Am J Surg. 1975 Dec;130(6):749-55 [1242874.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1296-300 [17031398.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jan;14(1):139-48 [15062387.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):81-4 [8850266.001]
  • [Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):73-8 [7834432.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2826-32 [17026561.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):89-96 [8696551.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 19585173.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


20. Ito Y, Suzuki M, Oyamada Y, Kou H, Takeshita K, Asano K, Yamaguchi K: [A case of relapsed small cell lung cancer recognized by simple metastasis to the duodenum]. Nihon Kokyuki Gakkai Zasshi; 2001 Jan;39(1):30-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of relapsed small cell lung cancer recognized by simple metastasis to the duodenum].
  • We describe a case of relapsed small cell lung cancer (SCLC) recognized by a duodenal tumor, its probable metastasis.
  • Chemotherapy consisting of CDDP and VP-16 followed by thoracic irradiation at a total dose of 50 Gy was performed from October 1996 to August 1997, resulting in CR (Complete Response) of the tumor.
  • In April of 1999, a mass surrounding the duodenum was found through an abdominal CT survey for tumor relapse, but no other tumors were detected in a series of CT scans or inbone scintigraphy.
  • Subsequent fiberscopy of the upper gastrointestinal tract revealed an ulcerative tumor extensively invading the mucosa of the duodenal bulb.
  • Biopsy specimens obtained from the duodenal tumor showed small-cell carcinoma with features similar to those of SCLC found in 1996, suggesting that SCLC of the left lung metastasized to the duodenal wall.
  • Chemoradiotherapy with 4 cycles of CDDP and VP-16 followed by abdominal irradiation at a dose of 30 Gy was given again from May to September 1999, producing good PR (Partial Response).
  • Although metastasis of SCLC to the duodenum seldom occurs, this report indicates that its early detection and effective treatment may prevent serious symptoms caused by obstruction of the duodenum or the papilla Vater.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Duodenal Neoplasms / secondary. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296383.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


21. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol; 2010 May;49(4):474-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
  • BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven.
  • We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma.
  • MATERIAL AND METHODS: We identified 54 patients with small bowel adenocarcinoma who underwent margin-negative surgical resection and were evaluated after surgery at the University of Texas, M. D.
  • RESULTS: Median age was 55 years and primary tumor site was duodenum in 67%, jejunum in 20%, and ileum in 13%.
  • Thirty patients (56%) received adjuvant therapy consisting of systemic chemotherapy with or without radiation in 28 and radiation alone in two.
  • Patients who received adjuvant therapy had significantly higher tumor stage and rate of lymph node involvement.
  • Five-year DFS and OS did not differ between treatment groups.
  • In multivariate analysis, the use of adjuvant therapy was associated with improved DFS (HR 0.27; 95% CI 0.07-0.98, P = 0.05) but not OS (HR 0.47; 95% CI 0.13-1.62, P = 0.23).
  • In patients with a high risk of relapse (defined as a lymph node ratio >or=10%), adjuvant therapy appeared to improve OS, P = 0.04, but not DFS, P = 0.15.
  • DISCUSSION: The use of adjuvant therapy for curatively resected small bowel adenocarcinoma was associated with an improvement in DFS.
  • This finding strongly supports further investigation of adjuvant chemotherapy in this tumor type.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Disease-Free Survival. Duodenal Neoplasms / therapy. Female. Follow-Up Studies. Humans. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397775.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Klose KJ, Heverhagen JT: Localisation and staging of gastrin producing tumours using cross-sectional imaging modalities. Wien Klin Wochenschr; 2007;119(19-20):588-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cross sectional imaging in the assessment of gastrinomas has three major applications: Tumor localization (sporadic gastrinoma, MEN I) in patients undergoing primary or secondary surgery.
  • Post-surgery follow-up and monitoring of bio- or chemotherapy.
  • Detection of primary tumors is strongly correlated with their size.
  • However, the sensitivity of surgical assessment of the mostly small tumors by experienced surgeons is much higher than that of any imaging modality.
  • Due to the absent radiation exposure, MRI is increasingly utilized to monitor the response of metastases under systemic therapy, e.g. in clinical trials.
  • [MeSH-major] Duodenal Neoplasms / pathology. Gastrinoma / pathology. Gastrins / blood. Magnetic Resonance Imaging. Pancreatic Neoplasms / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Angiography. Clinical Trials as Topic. Duodenum / pathology. Humans. Liver / pathology. Liver Neoplasms / blood. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Multiple Endocrine Neoplasia Type 1 / blood. Multiple Endocrine Neoplasia Type 1 / diagnosis. Multiple Endocrine Neoplasia Type 1 / pathology. Neoplasm Staging. Pancreas / pathology. Ultrasonography. Zollinger-Ellison Syndrome / blood. Zollinger-Ellison Syndrome / diagnosis. Zollinger-Ellison Syndrome / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1998 Jul;22(7):651-7; discussion 657-8 [9606277.001]
  • [Cites] World J Surg. 2004 Dec;28(12 ):1317-22 [15517479.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):70-8 [15625361.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):26-34 [8644985.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Chirurg. 2005 Mar;76(3):217-26 [15688179.001]
  • [Cites] Radiology. 2000 Feb;214(2):483-90 [10671597.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):138-44 [8342993.001]
  • [Cites] Digestion. 2000;62 Suppl 1:39-44 [10940686.001]
  • [Cites] Dig Dis Sci. 1993 Jul;38(7):1318-28 [8325191.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2005 May;13(2):313-30 [15935314.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1437-9 [7484581.001]
  • (PMID = 17985093.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Gastrins
  • [Number-of-references] 16
  •  go-up   go-down


23. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine carcinoma of the stomach is an uncommon tumor, usually associated with highly malignant biological behavior and extremely poor prognosis.
  • An upper gastrointestinal endoscopy revealed a 4x4-cm fungating tumor with its fundus locating mainly in the duodenal bulbus and extending to the gastric antrum, and tumor biopsy revealed the histological findings of adenocarcinoma.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • The patient's disease was diagnosed as primary duodenal cancer with regional lymph node metastases preoperatively.
  • Histopathologically, the origin of the primary tumor was considered as a gastric origin, and the tumor was composed of diffused small cells with a moderate mitotic index and occasional rosette formation.
  • Immunohistochemical investigations of the neoplastic cells confirmed the tumor to be neuroendocrine carcinoma.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down


24. Das BC, Kawarada Y: Long-term survival after treatment of gastric carcinoma with liver metastases. A case report. Hepatogastroenterology; 2003 Nov-Dec;50(54):2282-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after treatment of gastric carcinoma with liver metastases. A case report.
  • Radiographic and endoscopic studies showed a Borrmann type I gastric carcinoma on the anterior surface of the body of the stomach near the greater curvature, and a metastatic work-up demonstrated two masses in the right lobe of the liver (segment 6 and 8).
  • Ligation of the right portal vein and intraoperative common hepatic artery chemotherapy (one shot) was performed to destroy any non-visible metastatic tumors in the right lobe of the liver.
  • An aneurysm of the common hepatic artery developed after another shot of chemotherapy through the celiac artery one month after the operation.
  • The aneurysm ruptured, and a small fistula formed between the aneurysm and the duodenum.
  • The aneurysm was successfully treated by aneurysmectomy, and the perforated duodenal wall was managed by catheter duodenostomy.
  • The patient is alive and pursuing his previous occupation with no evidence of tumor recurrence.
  • Removal of the primary and metastatic lesions with portal vein ligation and intra-arterial chemotherapy is therefore effective as an active measure to prolong the survival time of gastric carcinoma patients with metastases limited to a single lobe of the liver.
  • [MeSH-minor] Aneurysm, Ruptured / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Follow-Up Studies. Hepatic Artery / surgery. Humans. Jejunostomy. Ligation. Male. Middle Aged. Portal Vein / surgery. Postoperative Complications / surgery. Reoperation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14696518.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


25. Schmidt C, Kasim E, Schlake W, Gerken G, Giese T, Stallmach A: TNF-alpha antibody treatment in refractory collagenous sprue: report of a case and review of the literature. Z Gastroenterol; 2009 Jun;47(6):575-8
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-alpha antibody treatment in refractory collagenous sprue: report of a case and review of the literature.
  • Collagenous sprue (CS) is a rare disease characterized by celiac type small bowel malabsorption that is resistant to gluten free diet (GFD) and is associated with a poor prognosis.
  • A 27-year-old man developed watery diarrhea with weight loss and abdominal pain.
  • Duodenal biopsies showed a subtotal villous atrophy with an extensive subepithelial layer of collagenous fibers.
  • High dose steroid treatment (75 mg prednisone) in combination with azathioprine (150 mg) reduced diarrhea but did not induce complete remission.
  • Based on strongly elevated mucosal TNF-alpha transcript concentrations we introduced infliximab (5 mg/kg body weight) into therapy.
  • This case suggests that infliximab is an effective treatment in complicated cases of collagenous sprue.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Celiac Disease / diagnosis. Celiac Disease / drug therapy
  • [MeSH-minor] Adult. Chronic Disease. Drug Resistance. Humans. Infliximab. Male. Treatment Outcome. Tumor Necrosis Factor-alpha / immunology

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533547.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  • [Number-of-references] 18
  •  go-up   go-down


26. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A: Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol; 2009 Jul;35(7):739-45
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To explore the effect of preoperative imatinib mesylate (IM) in patients with unresectable or locally advanced primary gastrointestinal stromal tumor (GIST).
  • RESULTS: Fifteen patients (1 esophageal, 7 gastric, 3 duodenal, 4 rectal GISTs) received preoperative IM for a median of 9 months.
  • All patients had tumor shrinkage, with a median size reduction of 34%.
  • In all cases an improvement of the originally planned surgical procedure was obtained: 3 patients initially considered unresectable underwent complete surgery; 7 patients with initial indication for extensive surgery were more conservatively operated on; 4 patients initially deemed at high perioperative risk underwent safe surgery.
  • Due to the small sample size, no association between tumor shrinkage and tumor site, size, IM duration, mutational status and pathological response could be formally explored.
  • It should be therefore always be considered before embarking on a major surgical procedure.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Aged. Benzamides. Combined Modality Therapy. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoadjuvant Therapy. Preoperative Care. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110398.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


27. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY: Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol; 2008 Aug;32(8):1130-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal antibodies (mAbs) against the cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule are used as an adjuvant to experimental tumor immunization protocols in the treatment of malignant melanomas and ovarian cancers.
  • Aside from noted early therapeutic successes, a spectrum of adverse effects, including severe gastroenteritis, has been reported.
  • We report herein our observations of 5 patients who developed severe gastrointestinal toxicity affecting the gastric, small intestinal, and colonic mucosa.
  • Cryptitis and glandular inflammation were observed in the colon, ileum, and stomach, whereas villous blunting was present in the ileal and duodenal mucosa.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antigens, CD / immunology. Gastric Mucosa / drug effects. Gastroenteritis / chemically induced. Immunohistochemistry. Intestinal Mucosa / drug effects. Neoplasms / drug therapy. T-Lymphocyte Subsets / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / immunology. Adenocarcinoma / pathology. Aged. CTLA-4 Antigen. Diarrhea / chemically induced. Diarrhea / immunology. Female. Humans. Male. Melanoma / drug therapy. Melanoma / immunology. Melanoma / pathology. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18545145.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / ipilimumab
  •  go-up   go-down






Advertisement